Table Graph
      published meta-analysis   sensitivity analysis   studies

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsACTIV-2 (BRII-196 and BRII-198), 0 0.05 [0.00; 0.94] 0.05[0.00; 0.94]ACTIV-2 (BRII-196 and BRII-198), 010%837NAnot evaluable hospitalization or deathdetailed resultsACTIV-2 (BRII-196 and BRII-198), 0 0.22 [0.05; 0.91] 0.22[0.05; 0.91]ACTIV-2 (BRII-196 and BRII-198), 010%NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-05-05 01:22 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 887 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons